Abstract library

43 results for "tryptophan metabolism".
#2999 Aberrant Tryptophan Metabolism in Stromal Cells Is Associated with Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
Introduction: Increased levels of serotonin secretion are associated with mesenteric fibrosis (MF) in small intestinal neuroendocrine tumors (SI-NETs). However, only a proportion of patients with increased serotonin production will develop mesenteric fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Drs. Anela Blazevic
#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors
Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Pr Frederique Savagner
Authors: Savagner F, Le Pennec S, ...
#1099 Niacin (vitamin B3) Suppletion in Patients with Serotonin Producing Neuroendocrine Tumors
Introduction: Tryptophan is the precursor of serotonin and niacin (vitamin B3), critical for normal cellular metabolism. Tryptophan and niacin can be deficient in patients with serotonin producing neuroendocrine tumors (NETs). Niacin deficiency can lead to symptoms including pellagra.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Others
Presenting Author: MD Grietje Bouma
#2906 Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors
Introduction: Metabolic changes are observed in early and late stages of Pancreatic Neuroendocrine Tumors (PanNET) in mouse models. In human PanNET, RNA-expression analysis showed changes in glucose metabolism in more aggressive PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Konstantin Bräutigam
#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MBBS Kishen Patel
Authors: Patel K, Nahar A, Elhassan Y, Shah T, ...
#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...
#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K, ...
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
#351 Comparison of 68Ga-Somatostatin Analogues, 18F-DOPA and 18F-FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Early detection of recurrences is a crucial step in the management of patients (pts) with medullary thyroid carcinoma (MTC). Currently, there is growing interest for PET tracers in MTC such as: 18F-FDG (reflecting glucose metabolism), 18F-DOPA (reflecting amine decarboxylation), 68Ga-somatostatin analogues (reflecting somatostatin receptors expression)
Conference:
Category: Basic
Presenting Author: Dr. Giorgio Treglia
#429 Bronchial Carcinoid Response to mTOR Inhibitors Depends on mTOR Expression Levels
Introduction: Bronchial carcinoids (BCs), originating from endocrine cells dispersed in the respiratory epithelium, can be divided into typical (TBC) and atypical (ABC). TBC are less aggressive, smaller, and much less likely to metastasize, while ABC are more aggressive and metastasize. mTOR has a central role in regulating cell growth, metabolism, and apoptosis. A differential mTOR activation in BCs has been previously demonstrated, suggesting that mTOR pathway might play a predictive role in patients eligible for mTOR-targeted therapies
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Teresa Gagliano
Keywords: BC, mTOR